UK Boosts Cell and Gene Therapy with New Manufacturing Center
UK Business Secretary Greg Clark and Science Minister Sam Gyimah today opened the Cell and Gene Therapy Catapult’s (CGT Catapult) unique cell and gene therapy manufacturing center in Stevenage, UK. Backed by over £60 million ($84m) of UK Government investment from its Industrial Strategy, the center will support and develop the rapidly growing global cell and gene therapy industry in the UK while demonstrating the government’s modern Industrial Strategy in action. The center will also supply the network of world-first, UK-based Advanced Therapies Treatment Centres (ATTCs) formed as part of the government’s investment of £146 million ($204m) through its Industrial Strategy Challenge Fund in medicines manufacturing. Greg Clark commented: “We are determined to make the UK the most innovative nation in the world through our Industrial Strategy and its Grand Challenges, which is why we are investing a record £7 billion ($9.8 bn) in R&D by 2021, the highest increase in 40 years, and have committed to investing 2.4% of GDP on R&D by 2027.” For more information, visit ct.catapult.org.uk or http://www.gov.uk/innovate-uk.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
